FDA approves Grifols’ Xembify to treat primary immunodeficiencies

This article was originally published here

According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients

The post FDA approves Grifols’ Xembify to treat primary immunodeficiencies appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply